PIK3CA and Hyperglycemia: Hyperglycemia was one of the most frequent AEs found with PIK3CA inhibitors, with rates equal to 64% in SOLAR-1 [85], 43% in BELLE-2 [57], 37% in BELLE-3 [58], and 40% in the SANDPIPER trial [110].